Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

• Joshua F. Zeidner,
• Flora Mazerolle,
• Jonathan Norton,
• Antoine Regnault,
• Fjoralba Kristo,
• Heather Romero,
• Robert J. Fram,
• Douglas V. Faller,
• Mehul Dalal,
• Lionel Ades,
• Mikkael A. Sekeres

Affiliations

Joshua F. Zeidner

University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Flora Mazerolle

Modus Outcomes, a division of THREAD, Lyon

Jonathan Norton

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

Antoine Regnault

Modus Outcomes, a division of THREAD, Lyon

Fjoralba Kristo

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

Heather Romero

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

Robert J. Fram

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

Douglas V. Faller

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

Mehul Dalal

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

Lionel Ades

AP-HP, Hôpital Saint Louis, Paris, France; University of Paris, and INSERM U944, Paris

Mikkael A. Sekeres

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL